A parallel might be drawn between the effect of fenofibrate (a PPARα agonist) in endometrial cancer and thiazolidenediones (TZDs, PPARγ agonists), such as rosiglatazone and troglitazone, in breast cancer. The gene discussed is PPARA; the disease is endometrial cancer.